Evidence map›Paper›PMID 34744265›Full record

Trial reportActa clinica Croatica2021

EFFICACY OF CYCLOCRYOTHERAPY AND TRANSSCLERAL DIODE LASER CYCLOPHOTOCOAGULATION IN THE MANAGEMENT OF REFRACTORY GLAUCOMA.

Aleksandar Miljković, Nikola Babić, Vladimir Čanadanović, Sofija Davidović, Jelena Ljikar, Marija Vasin

Open access · diamondAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Acta clinica Croatica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Management and outcomes of primary open-angle glaucoma.Journal of family medicine and primary care · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Aleksandar Miljković1Faculty of Medicine, University of Novi Sad, Novi Sad, Vojvodina, Serbia; 2Eye Department, Clinical Centre of Vojvodina, Novi Sad, Vojvodina, Serbia.
Nikola Babić1Faculty of Medicine, University of Novi Sad, Novi Sad, Vojvodina, Serbia; 2Eye Department, Clinical Centre of Vojvodina, Novi Sad, Vojvodina, Serbia.
Vladimir Čanadanović1Faculty of Medicine, University of Novi Sad, Novi Sad, Vojvodina, Serbia; 2Eye Department, Clinical Centre of Vojvodina, Novi Sad, Vojvodina, Serbia.
Sofija Davidović1Faculty of Medicine, University of Novi Sad, Novi Sad, Vojvodina, Serbia; 2Eye Department, Clinical Centre of Vojvodina, Novi Sad, Vojvodina, Serbia.
Jelena Ljikar1Faculty of Medicine, University of Novi Sad, Novi Sad, Vojvodina, Serbia; 2Eye Department, Clinical Centre of Vojvodina, Novi Sad, Vojvodina, Serbia.
Marija Vasin1Faculty of Medicine, University of Novi Sad, Novi Sad, Vojvodina, Serbia; 2Eye Department, Clinical Centre of Vojvodina, Novi Sad, Vojvodina, Serbia.
University of Novi Sad · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treating advanced glaucoma often requires numerous therapeutic modalities in order to achieve the desired intraocular pressure (IOP) reduction. The purpose of this study was to evaluate the IOP lowering efficacy of both cyclocryotherapy (CCT) and transscleral diode laser cyclophotocoagulation (TS-DCPC) in the management of refractory primary open-angle glaucoma. This prospective, randomized, controlled clinical trial included 40 patients (40 eyes) with refractory glaucoma treated at the Eye Department, Clinical Center of Vojvodina, Novi Sad, Serbia, between January 2016 and June 2019. Twenty patients underwent CCT (group 1), while another twenty patients were treated with TS-DCPC (group 2). Each patient underwent complete eye examination on the treatment day, as well as follow-up eye examinations 7 days and 1, 6 and 12 months after the intervention, when IOP and number of anti-glaucoma drugs used were recorded. The median baseline IOP was 36.50 mm Hg (IQR, 28.75-42.00) in group 1 and 27.00 mm Hg (IQR, 22.00-35.00) in group 2. Follow-up measurements of IOP in group 1 showed the following results: 16.50 mm Hg (IQR, 7.75-20.00) (60% decrease from the baseline value), 12.00 mm Hg (IQR, 9.25-18.00) (67% decrease from the baseline value), 9.00 mm Hg (IQR, 2.00-13.75) (73% decrease from the baseline value), and 9.50 (IQR, 2.50-12.00) (75% decrease from the baseline value) after 7 days, 1, 6 and 12 months, respectively. Follow-up measurements of IOP in group 2 showed the following results: 16.00 mm Hg (IQR, 10.00-17.00) (48% decrease from the baseline value), 14.00 mm Hg (IQR, 10.00-16.00) (56% decrease from the baseline value), 14.00 mm Hg (IQR, 12.25-16.50) (43% decrease from the baseline value) and 14.00 mm Hg (IQR, 11.25-15.75) (53% decrease from the baseline value) after 7 days, 1, 6 and 12 months, respectively. The mean number of antiglaucoma drugs used decreased from 4 to 0.65±0.81 and 2.25±1.07 in groups 1 and 2, respectively. In conclusion, study results confirmed the CCT and TS-DCPC to have a rapid and statistically significant ocular hypotensive effect in eyes with refractory glaucoma at one-year follow-up.

Indexed as

GlaucomaGlaucoma, Open-AngleCiliary BodyFollow-Up StudiesHumansIntraocular PressureLaser CoagulationLasers, SemiconductorProspective StudiesRetrospective StudiesTreatment OutcomeVisual AcuityCyclocryotherapyDiode laser cyclophotocoagulationIntraocular pressureRefractory glaucoma

Identifiers

PMID34744265
PMCPMC8564844
OpenAlexW3205952767

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.